SCHEMBL23922917

SCHEMBL23922917

CCC(=O)OCCON1C(=O)CCC1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
BLM P54132 1/20 0.41
WRN Q14191 1/20 0.41
HIF1A Q16665 1/20 0.41
NAAA Q02083 1/20 0.40
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.36
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.34
MAPT P10636 1/20 0.34
DGKA P23743 1/20 0.32
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21352287 0.86 DGKA (0.42) ALOX12GAASMN1; SMN2ALDH1A1KDM4E
SCHEMBL27664746 0.85 ALOX12 (0.45) ALOX12SMN1; SMN2ALDH1A1HPGDBLM
SCHEMBL8744647 0.82 ALOX12 (0.46) ALOX12SMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL28236067 0.81 ALOX12 (0.41) ALOX12GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL20786977 0.81 ALOX12 (0.43) ALOX12SMN1; SMN2HPGDKDM4EPOLB
SCHEMBL13540116 0.79 GAA (0.41) ALOX12GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL28145893 0.78 KDM4E (0.37) ALOX12SMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL9329901 0.78 DGKA (0.37) GAAALDH1A1HPGDCYP1A2CYP2C19
SCHEMBL16290005 0.78 ALOX12 (0.53) ALOX12GAASMN1; SMN2ALDH1A1HPGD
SCHEMBL4702471 0.77 NAAA (0.47) ALOX12GAAALDH1A1HPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110201234-A A kind of used in tissue engineering prostatic cell micro-capsule and preparation method thereof 山东百多安医疗器械有限公司 2019-09-06 CN claimed
CN-109893657-B Gene delivery carrier, drug compound, anti-pulmonary fibrosis drug and application 中国人民解放军军事科学院军事医学研究院 2022-04-29 CN disclosed
US-20220125939-A1 METHOD OF PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES JENKEM TECHNOLOGY CO., LTD. (TIANJIN) (CN) 2022-04-28 US disclosed
EP-3896079-A1 METHOD OF PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES Jenkem Technology Co. Ltd. (Tianjin) (CN) 2021-10-20 EP disclosed
CN-101357986-B Polyethylene glycol functional derivative and preparation method thereof BIO CANCER TREATMENT INT LTD 2013-06-05 CN disclosed
CN-101357986-A Polyethylene glycol functional derivative and preparation method thereof KANGDA MEDICAL SCIENCE AND TEC (HK) 2009-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125939-A1 METHOD OF PREPARING PEGYLATED BIOMOLECULES HAVING CONTROLLABLE BINDING SITES IL2RA, IL2, HBG2 ALOX12 3109/4885GAA 1565/4885SMN1; SMN2 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.